The investors asked the companies to include the proposals on proxy ballots that will be put to shareholder votes at annual meetings this spring. Different members of the group sent the proposals to different drug companies. Ms. Meyer said Interfaith investors plan to attend several of the drug companies’ annual meetings to ask boards of directors about drug pricing. She said price increases pose a risk to the companies’ long-term prosperity because they could hurt corporate reputations and trigger government action. She also said the U.S. health-care system can’t afford continuing drug price increases, and the lack of transparency is hurting the system.

Source: Wall Street Journal March 01, 2017 22:07 UTC